Items tagged with Vaccines

European researchers identify a mechanism of protection of the new TB vaccine MTBVAC (post)

Researchers at the University of Zaragoza (belonging to CIBERES) and the biopharmaceutical vaccine company Biofabri in Porrino, Spain in partnership with the TuBerculosis Vaccine Initiative (TBVI) are developing a new TB vaccine, MTBVAC. MTBVAC, a live attenuated M.tuberculosis vaccine, has been shown to provide improved protection as compared to BCG and the mechanism behind this greater efficacy has been hypothesized to be due to the ability of MTBVAC to present a wider collection of antigens of M. tuberculosis.

Genetic tweaks to TB could speed up discovery of a new vaccine (post)

“OK, smell this,” says Jeff Wagner, a Harvard postdoc of immunology and infectious disease. He’s pointing to the two flasks of bacteria in front of me. I breathe cautiously from the first vial of yellowish broth. Nothing. “Now this one,” he says, with an identical looking sample. And I’m hit with it: a distinct mint aroma like someone melted down a pack of breath mints.

Texas Biomed part of team receiving five-year, $4.4 million NIH grant for novel TB vaccine testing (post)

San Antonio, Texas (August 21, 2017) – Tuberculosis (TB) is the leading cause of death due to infectious disease worldwide. Texas Biomedical Research Institute Associate Scientist Dr. Marie-Claire Gauduin has partnered with Dr. Chinnaswamy Jagannath, professor of pathology and laboratory medicine at McGovern Medical School at UTHealth in Houston to test a modified TB vaccine that, if effective, could prove more powerful and provide longer lasting immunity. Dr. Gauduin and Dr. Jagannath are principal investigators on this study.

BCG jab may protect against TB for nearly twice as long as previously thought (post)

The world’s only licensed tuberculosis (TB) vaccine could offer protection against the disease for nearly twice as long as previously thought, according to new research published in the International Journal of Epidemiology.

Quratis teams with IDRI on TB vaccine (post)

SEATTLE & SEOUL | Aug. 30, 2017: Quratis Inc. announced Wednesday that the company had applied for the phase 2 of clinical trials in Korea for an adult tuberculosis vaccine developed by scientists at the Infectious Disease Research Institute (IDRI). The clinical trial will evaluate the safety and efficacy of the vaccine in the Korean population.

(post with image)

Novel vaccine trial design aims to answer key TB questions (post with simple image)

Prevention of infection study underway in South Africa.

The Lancet journals: World TB Day media alert (post with simple image)

For World TB Day 2014, The Lancet group publishes a Series of papers to highlight the need for global collaboration to diagnose, treat, and cure people with tuberculosis.

HIV i-Base/TAG: 2014 Pipeline Report (post with simple image)

Latest annual review on pipeline drugs for adults and children, strategies for cure and prevention for HIV, HCV, TB and vaccine research.

Page 8 of 10 · Total posts: 0

←First 7 8 9 Last→